Chemotherapy & Immunotherapy
Our Clinical Trials Find out about new research studies for mesothelioma 
|
|
|
Our medical oncologists not only care for a large number of patients with pleural mesothelioma but also conduct numerous clinical trials testing new drugs and novel approaches. They have led a national study assessing the role of chemotherapy before extrapleural pneumonectomy and radiation for patients with early-stage disease [PubMed Abstract]. In addition, they are exploring the use of immunotherapies (treatments that stimulate the body's immune system to attach and kill cancer cells) for mesothelioma and recently completed a study with a WT-1 vaccine developed here. (The Wilms tumor protein, encoded by the WT-1 gene, can be used as a target for a patient's immune system.)
Currently, they are leading an international phase III study of a new oral drug called vorinostat for patients who previously received treatment with chemotherapy.
Focus on the Patient
Communication with patients and caregivers is a priority at Memorial Sloan-Kettering. We believe that treating the whole person, not just the disease, is the best approach for patients and family members. At Memorial Sloan-Kettering, we offer a broad range of emotional support programs designed to help patients and family members cope with the range of issues related to life during and after cancer treatment.
Our team of experts, which includes thoracic surgeons, radiation oncologists, and medical oncologists, provides experienced, up-to-date, and thoughtful care for patients diagnosed with pleural mesothelioma.